Supernus Pharmaceuticals
SUPN
SUPN
330 hedge funds and large institutions have $2.84B invested in Supernus Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 61 funds opening new positions, 114 increasing their positions, 112 reducing their positions, and 32 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding
Funds holding: →
more capital invested
Capital invested by funds: $ → $
2% more repeat investments, than reductions
Existing positions increased: 114 | Existing positions reduced: 112
3.27% less ownership
Funds ownership: 102.87% → 99.6% (-3.3%)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Holders
330
Holding in Top 10
3
Calls
$5.9M
Puts
$5.35M
Top Buyers
| 1 | +$112M | |
| 2 | +$24.5M | |
| 3 | +$15.8M | |
| 4 |
Aberdeen Group
Edinburgh,
United Kingdom
|
+$13.2M |
| 5 |
MIM
MetLife Investment Management
Whippany,
New Jersey
|
+$13.2M |
Top Sellers
| 1 | -$121M | |
| 2 | -$60.4M | |
| 3 | -$46.9M | |
| 4 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$28.5M |
| 5 |
Goldman Sachs
New York
|
-$24.4M |
